EZH2 and lung cancer: To test whether EZH2 affects the sensitivity of LUAD cells to EGFR-TKIs, we knocked down EZH2 expression in lung cancer cells using siRNA and subjected the cells to the CCK8 assay after exposure to different concentrations of gefitinib for 24–48 h.